(bupivacaine liposome injection)
Pivotal studies have demonstrated the safety and efficacy of EXPAREL in patients undergoing bunionectomy and
The clinical benefit of the attendant decrease in opioid consumption was not demonstrated.
Important Safety Information:
EXPAREL is contraindicated in obstetrical paracervical block anesthesia. EXPAREL has not been studied for use in
patients younger than 18 years of age. Non-bupivacaine-based local anesthetics, including lidocaine, may cause an
immediate release of bupivacaine from EXPAREL if administered together locally. The administration of EXPAREL
may follow the administration of lidocaine after a delay of 20 minutes or more. Other formulations of bupivacaine
should not be administered within 96 hours following administration of EXPAREL. Monitoring of cardiovascular
and neurological status, as well as vital signs should be performed during and after injection of EXPAREL as with
other local anesthetic products. Because amide-type local anesthetics, such as bupivacaine, are metabolized
by the liver, EXPAREL should be used cautiously in patients with hepatic disease. Patients with severe hepatic
disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic
plasma concentrations. In clinical trials, the most common adverse reactions (incidence ≥10%) following EXPAREL
administration were nausea, constipation, and vomiting.
References: 1. Gorfine SR et al. Dis Colon Rectum. 2011;54( 12):1552-1559. 2. Golf M et al. Adv Ther. 2011; 28( 9):776-788.
Long-Lasting Pain Control With
Less Need for Opioids1, 2
• Indicated for administration into the surgical site
to produce postsurgical analgesia
• Reduce pain and opioid requirements1, 2 without
the need for catheters or pumps
©2014 Pacira Pharmaceuticals, Inc., Parsippany, NJ 07054 PP-EX-US-0502 11/14
Please see brief summary of Prescribing Information on opposite page.
For more information, visit www.EXPAREL.com
Pain Control With
A Single Dose